Oxlumo
lumasiran · Alnylam Netherlands B.V.
ORPHAN PRIME AUTHORISED IN THE EUWhat Oxlumo is used for
Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Oxlumo
- Active substance
- lumasiran
- Disease area
- Hyperoxaluria, Primary
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AX18
- Marketing authorisation holder
- Alnylam Netherlands B.V.
- Authorised in the EU since
- 2020
Official information
In the USA
Same active substance: Oxlumo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Oxlumo used for?
Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
What is the active substance in Oxlumo?
Oxlumo contains lumasiran.
Who makes Oxlumo?
The EU marketing authorisation holder is Alnylam Netherlands B.V..
Is Oxlumo an orphan medicine?
Yes. Oxlumo is designated an orphan medicine in the EU, for a rare disease (Hyperoxaluria, Primary).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU